Surgeons are increasingly favoring spine biologics due to the limited pain and invasiveness, according to a Transparency Market Research report.
Here are five takeaways:
1. In spine surgery, the dominant biologic is bone morphogenetic protein.
2. The costliness of the process will deter the growth of the global spine biologics market, however.
3. North America dominates the global market because of developed technologies and hospitals, medical literacy and increases in the citizens' per capita income.
4. The Asia-Pacific market will likely grow at a significant rate in the coming years because of the rising population and improving medical technology. Additionally, industry demand will increase in India and China.
5. Key companies include Alphatec Spine, DePuy Synthes, Medtronic, Stryker Corp., Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.